Literature DB >> 7356895

Quantitative analysis of the disopyramide concentration-effect relationship.

B Whiting, N H Holford, L B Sheiner.   

Abstract

1. A combined pharmacokinetic-pharmacodynamic model has been used to analyse the relationship between QT prolongation and changes in plasma concentration which occurred after disopyramide was given intravenously and orally to eight healthy subjects. 2. The pharmacokinetic models appropriate to intravenous and oral disopyramide have been extended by an 'effect compartment' which has no influence on the predetermined mass of drug in the body. 3. The model incorporates an adjustment for lag of effect behind any rapid changes in plasma concentration such as occur in the early distributive phase following intravenous administration. This permits calculation of the proportionality constant relating plasma concentration to effect. 4. Irrespective of the route of administration the mean (+/- s.d.) prolongation of the QT interval was 14.5 +/- 6.5 ms/micrograms ml-1. 5. There was no evidence that metabolite produced during first pass after oral administration made any significant contribution to effect. 6. This modelling technique should be applicable to the study of the concentration-effect relationship of a number of other drugs, both in health and in disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7356895      PMCID: PMC1429920          DOI: 10.1111/j.1365-2125.1980.tb04799.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  Pharmacodynamics of the antiarrhythmic disopyramide in healthy humans: correlation of the kinetics of the drug and its effects.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

2.  Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

3.  Relationship between the pharmacokinetics and pharmacodynamics of procainamide.

Authors:  R L Galeazzi; L Z Benet; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

4.  Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.

Authors:  S M Bryson; B Whiting; J R Lawrence
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

5.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

  5 in total
  40 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Holford NHG and Sheiner LB "Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models", Clin Pharmacokin 6:429-453 (1981)-The Backstory.

Authors:  Nick Holford
Journal:  AAPS J       Date:  2011-10-18       Impact factor: 4.009

3.  Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses.

Authors:  Lena E Friberg; Geoffrey K Isbister; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

4.  A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers.

Authors:  J D Gemmill; C A Howie; P A Meredith; A W Kelman; H S Rasmussen; W S Hillis; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

5.  Plasma protein binding of disopyramide in pregnant and postpartum women, and in neonates and their mothers.

Authors:  H Echizen; M Nakura; T Saotome; S Minoura; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

6.  Kinetics of ajmaline disposition and pharmacologic response in beagle dogs.

Authors:  M Yasuhara; Y Hashimoto; K Okumura; R Hori; T Sakurai; C Kawai
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

7.  Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases.

Authors:  H Echizen; S Saima; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

8.  Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.

Authors:  M L Aitio
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

9.  Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.

Authors:  K M Giacomini; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.